High response rates with talquetamab in advanced myeloma
NEW ORLEANS — A new standard antibody, talquetamab, has shown high response rates in patients with heavily pretreated multiple myeloma in Phase 1 and now Phase 2 studies, which have been submitted for approval. “Talquetamab is a new agent directed against a new antigenic target in myeloma,” explained lead researcher Ajai Chari, MD, of Mount …
High response rates with talquetamab in advanced myeloma Read More »
